It should be highlighted that local overexpression of LOX by aortic adenoviral delivery limited the development of established CaCl2-induced AAA, at least in part by inhibiting vascular smooth muscle cells (VSMC)-mediated MCP-1 secretion and JNK activity [14,16]. Here, LOX is linked to triple-A syndrome.